ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program

 In News

Xconomy Detroit – 7/6/15
by Sarah Schmid

ONL Therapeutics, a University of Michigan spin-out working on sight-preserving therapies for retinal diseases, announced that it has changed course in its drug development program. The company has promoted a new lead drug candidate and has expanded its planned clinical studies to include both dry and wet forms of age-related macular degeneration (AMD).

Leave a Comment

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search